Uplizna FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (First approved June 11, 2020)
Brand name: Uplizna
Generic name: inebilizumab-cdon
Dosage form: Injection
Company: Viela Bio
Treatment for: Neuromyelitis Optica Spectrum Disorder (NMOSD)
Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Development timeline for Uplizna
| Date | Article |
|---|---|
| Jun 13, 2020 | Approval FDA Approves Uplizna (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
